跳至主導覽
跳至搜尋
跳過主要內容
排序方式
Keyphrases
Activator of Transcription 3
7%
Angiogenesis
15%
Apparent Diffusion Coefficient
7%
Attenuation
7%
Bcl-xL
7%
Brain Glioma
7%
Cell Apoptosis
7%
Cell Growth
7%
Cell Survival
7%
Constitutively Active
7%
Dual Inhibitor
7%
EGFR mutation
100%
EGFRvIII
100%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
30%
Extracellular Signal-regulated Kinase 1/2
7%
Glioblastoma
15%
Glioma
100%
Inpatient Treatment
7%
Magnetic Resonance Imaging Analysis
7%
Multitarget Inhibitors
100%
Mutant Epidermal Growth Factor Receptor
7%
Overexpressing
23%
Phosphoinositide 3-kinase (PI3K)
7%
Phosphorylation
7%
Primary Glioma
7%
Receptor Tyrosine Kinase
100%
Receptor Tyrosine Kinase Inhibitor
7%
Signal Transducer
7%
Signaling Mediators
7%
Ther
7%
Three-dimensional (3D)
7%
Tumor Angiogenesis
15%
Tumor Growth
15%
U87 Cells
7%
U87MG
38%
Vandetanib
7%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
7%
Xenograft Model
7%
Neuroscience
Angiogenesis
36%
Cell Growth
9%
Cell Survival
9%
Epidermal Growth Factor Receptor
100%
Extracellular Signal-Regulated Kinases
9%
Glioma
100%
Kinase Insert Domain Receptor
9%
Magnetic Resonance Imaging
9%
Phosphoinositide 3-Kinase
9%
phosphorylation
9%
Programmed Cell Death
9%
Protein Kinase B
9%
Receptor Tyrosine Kinase
100%
Receptor Tyrosine Kinase Inhibitors
9%
STAT3
9%
Biochemistry, Genetics and Molecular Biology
Angiogenesis
36%
Apparent Diffusion Coefficient
9%
Cell Growth
9%
Cell Survival
9%
Epidermal Growth Factor Receptor
100%
Extracellular Signal-Regulated Kinases
9%
Kinase Insert Domain Receptor
9%
Magnetic Resonance Imaging
9%
Mediator
9%
Phosphoinositide 3-Kinase
9%
phosphorylation
9%
Programmed Cell Death
9%
Protein Kinase B
9%
Receptor Tyrosine Kinase
100%
Receptor Tyrosine Kinase Inhibitors
9%
STAT3
9%
Tumor Progression
18%
Wild Type
9%